| 3.46 -0.91 (-20.82%) | 06-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.51 |
1-year : | 8.17 |
| Resists | First : | 5.57 |
Second : | 7 |
| Pivot price | 4.57 |
|||
| Supports | First : | 3.27 | Second : | 2.72 |
| MAs | MA(5) : | 3.91 |
MA(20) : | 4.84 |
| MA(100) : | 9.04 |
MA(250) : | 21.79 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 23  |
D(3) : | 20.1 |
| RSI | RSI(14): 31.5 |
|||
| 52-week | High : | 55.9 | Low : | 3.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SHPH ] has closed above bottom band by 2.0%. Bollinger Bands are 60.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.88 - 3.91 | 3.91 - 3.93 |
| Low: | 3.35 - 3.38 | 3.38 - 3.4 |
| Close: | 3.43 - 3.46 | 3.46 - 3.5 |
Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.
Thu, 18 Jun 2026
Shuttle Pharmaceuticals Holdings Inc - TradingKey
Thu, 18 Jun 2026
Shuttle Pharmaceuticals Holdings Inc (SHPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Thu, 18 Jun 2026
Shuttle Pharmaceuticals Holdings Inc (SHPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Wed, 17 Jun 2026
Shuttle Pharmaceuticals Holdings Inc (SHPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Thu, 11 Jun 2026
1-for-10 reverse split reshapes Shuttle Pharma (NASDAQ: SHPH) stock - Stock Titan
Tue, 09 Jun 2026
AI drug firm with Dogecoin arm shrinks share count 10-for-1 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 8.2 (%) |
| Held by Institutions | 33.7 (%) |
| Shares Short | 23 (K) |
| Shares Short P.Month | 12 (K) |
| EPS | 0.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -81.7 % |
| Return on Equity (ttm) | -326.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -18.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | 34.59 |
| PEG Ratio | 0 |
| Price to Book value | 3.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|